Denovo Biopharma

A Novel Biomarker Discovery Solution for Personalized Drug Development Denovo Biopharma is a private San Diego based biotech company providing a novel biomarker solution to personalize drug development. The core technology of the company is its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effects. By identifying biomarkers correlated to patients'​ responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in targeted patient population to achieve higher efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in most therapeutic areas, such as oncology and neurological diseases. Denovo’s lead asset, liafensine, a first-in-class antidepressant in Phase 3 development. Liafensine has shown robust efficacy in ANK3-positive patients with treatment-resistant depression (TRD) in a pivotal study in addition to an excellent safety profile based on data from nearly 1500 individuals exposed to the drug. This non-psychedelic oral pill represents the first precision medicine in psychiatry with the potential to shift the treatment paradigm for TRD, a highly unmet medical need. We are seeking funding to complete one more pivotal study to file NDA.